Results 111 to 120 of about 114,702 (262)

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies [PDF]

Journal of Clinical Medicine, 2018
Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent.
Campbell, Robert, Chong, Geoffrey, Hawkes, Eliza A.   +2 more
openaire   +2 more sources

Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]

, 2015
OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye, Alexander R. Stainer, Amanda J. Unsworth, Jonathan M. Gibbins, Michael J. Fry, Oda A, Sakthivel Vaiyapuri   +6 more
core   +1 more source

Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next

Photochemistry and Photobiology, EarlyView.
The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal, Durdana Muntaqua, Gagan Chhabra, Nihal Ahmad   +3 more
wiley   +1 more source

Ibrutinib-associated osteonecrosis of the jaw

Oral Oncology Reports
Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL).
Annu Singh, Sion Na, Joseph M. Huryn, Cherry L. Estilo, Steven Horwitz, SaeHee K. Yom   +5 more
doaj   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

Arthritis Research & Therapy, 2011
IntroductionThe aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying ...
B. Chang, M. Huang, M. Francesco, Jun Chen, J. Sokolove, P. Magadala, W. Robinson, J. Buggy   +7 more
semanticscholar   +1 more source

Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca, Nicara Chantal Parr, Adriana Palmeri, Adrian Andronache, Hiroshi Arima, Giovanni Faga’, Brian Leuzzi, Laura Perucho, Michela Robusto, Maurizio Pasi, Federica Mainoldi, Daniele Fancelli, Mario Varasi, Gabriele Varano, Ciro Mercurio, Stefano Casola   +15 more
wiley   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]

, 2014
Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E, Carvajal, T, Castro, JE, Chang, J, Choi, MY, James, DF, Kipps, TJ   +6 more
core   +3 more sources